GENOPOLE IS THE LEADING FRENCH SCIENCE PARK DEDICATED TO LIFE SCIENCES. ITS CAMPUS - NEAR PARIS - COMBINES ACADEMIC AND PRIVATE

Transcription

1 Genopole French Biopark GENOPOLE IS THE LEADING FRENCH SCIENCE PARK DEDICATED TO LIFE SCIENCES. ITS CAMPUS - NEAR PARIS - COMBINES ACADEMIC AND PRIVATE RESEARCH LABORATORIES, UNIVERSITY/HIGHER EDUCATION FACILITIES, BIOTECHNOLOGY COMPANIES, AND AN INCUBATOR FOR BIOTECH START-UPS. Ï 23 ACADEMIC LABORATORIES INCLUDING 2 NATIONAL CENTERS Ï 2 NATIONAL PLATFORMS, 7 OPEN-ACCESS TECHNOLOGY PLATFORMS, 6 MAJOR TECHNICAL FACILITIES. Ï 57 BIOTECH COMPANIES, INCLUDING 35 FOUNDED AND INCUBATED BY GENOPOLE Ï 118 MILLION EUROS IN EQUITY RAISED BY GENOPOLE BASED COMPANIES Ï 70 MILLION EUROS IN EQUITY RAISED BY COMPANIES IN THE GENOPOLE 1 ER JOUR PRE-SEED FUND PORTFOLIO Ï 86,000 SQ METERS OF BUSINESS AND LAB ACCOMMODATION, INCLUDING Ï 26,530 SQ METERS OF FULLY-EQUIPPED LAB SPACE Ï 1 BIOTECH BUSINESS INCUBATOR WITH 2,600 SQ METERS OF FLOOR SPACE Ï 6 BUSINESS ACCOMMODATION MODULES, TOTALING 22,000 SQ METERS OF FLOOR SPACE THE ACCUMULATED INTELLECTUAL CAPITAL AND THE TECHNICAL, FINANCIAL AND LOGISTIC PLATFORM SET UP AT GENOPOLE ARE THE KEY FEATURES OF THIS UNIQUE BIOPARK, WHICH OFFERS TO PHARMACEUTICAL AND BIOTECH COMPANIES BUSINESS PARTNERSHIP AND RESEARCH COLLABORATION OPPORTUNITIES.

2 A Strategic Location Genopole : a pioneering site THE NUMBER ONE FRENCH BIOPARK, FOUNDED IN 1998 ON THE LINES OF AMERICAN AND EUROPEAN CLUSTERS. THE CAMPUS ALSO SERVED AS THE MODEL FOR A NETWORK OF GOVERNMENT-APPROVED GENOPOLE ORGANIZATIONS THROUGHOUT FRANCE. THE LEADING SECOND-STAGE BUSINESS INCUBATOR IN FRANCE, FOUNDED AND OPERATED BY THE ESSONNE CHAMBER OF COMMERCE AND INDUSTRY AND FULLY DEDICATED TO BIOTECH STARTUPS. THE FIRST EVER PRE-SEED FUND GENOPOLE 1 ER JOUR DEDICATED TO EARLY-STAGE FINANCING OF BIOTECH STARTUPS. THE FIRST EVER PHYSICAL AND GENETIC MAPS OF THE HUMAN GENOME, ESTABLISHED BY THE GÉNÉTHON LABORATORY, THE FIRST FRENCH LAB TO HAVE EQUIPPED ITSELF WITH LARGE- SCALE BIOLOGY INFRASTRUCTURE - FOUNDED AND FUNDED BY THE FRENCH MUSCULAR DYSTROPHY ASSOCIATION, THE ORGANIZER OF FRANCE S FIRST EVER TELETHON TV FUNDRAISING EVENT IN Real estate to meet all requirements Opening biotechs, new laboratories, and research units is a constant preoccupation for Genopole : this involves offering equipped premises and shared services to the scientific community and companies. Genopole has embarked on a strategy of making suitable and attractive premises available to companies and laboratories with three objectives in mind: watching over a spatial coherence within the Evry-Corbeil urban area (near Paris) in order to create a harmonious campus; offering space adapted to scientific needs at market prices; and setting up common services. Service infrastructure, technological, logistic and real estate support covering about 86,000 sq m (926,000 sq ft). Genopole has always focused on one essential mission: providing the best conditions for developing research and business projects.

3 Linking Science to Business Foster the development of biotech companies Genopole contributes actively to the creation of biotech companies by hosting entrepreneurs with innovative projects and offering them logistic, technical, managerial and financial support. Genopole provides support to start-up companies during their early years and thus optimizes their chances of success. Finally, Genopole is strongly involved in the economic development of Evry by encouraging life science businesses and major pharma companies to expand or relocate to the campus. Agro industry Material device 17% Companies by field of activity Environment 2% 7% 7% Bio-informatics 3% 8% Others Chemistry Biomedicine Healthcare 56% Therapeutic targeting 5.08% Drug research 28.81% Diagnostics 16.95% Drug delivery 5.08% Build up and stimulate a center of scientific excellence In partnership with France s main public-sector research institutes (CNRS, CEA, Inserm, Inra) and the Ile-de-France region s universities (Evry-Val d Essonne, Paris-VI, Paris-XIII, Versailles-Saint-Quentin), Genopole hosts and equips high-level research units. Their complementary research themes cover all the requisite fields for detailed understanding of the complexity of life. Academic labs by field of activity Engineering sciences 27% 8% 15% Genetics /Genomics Postgenomics 50% Preseed Fund Genopole 1 er Jour To assist with early stage financing, Genopole has set up a preseed fund called G1J. Since it was set up in 1999, G1J has invested in 25 start-ups with individual amounts varying from EUR 30,000 to EUR 100,000. To date, G1J portfolio companies have raised 70 million euros in equity (seed finance, first-, second- and third-round financing) by institutional investors. Bio-informatics Biomathematics Biophysics/Biochemistry

4 Directory Genop Biopharmaceuticals Companies target discovery / validation value chain in drug discovery drug discovery drug delivery diagnostics autoimmune cancer Abag Acriter Consulting Aisa Therapeutics AOK Engineering Atragene Bioinformatics Biofords Biogemma Biomethodes Biosystems International Biotom CellVax CellVir Celogos Centaure Metrix Delphia Laboratoires DNA Therapeutics DrugAbilis Epixis Flowgene Genecust Flowgene Gene Signal Genewave Genodyssee Genomining Genoplante Valor SAS Genoptics Genosafe IGNA Integragen IVF Biotech Robotics LTK Farma MacDermol Monoclonal Antibodies Therapeutics Nanobiogene Nautilus Biotech Nokad Novacyt Novagali Pharma ObeTherapy Biotechnology betherapy B I O T E C H N O L O G Y Partnerchip Sanofi Aventis Evry Genetics Center Sebia Serial Genetics Sinovia Sphergen Statlife Sysra Tech Innovation Texcell Theraclion Vaxon Biotech Viroxis Watchfrog

5 ole Companies Agri biotech Environment Chemistry & green chemistry Bioinformatics & informatics Material / Medical device therapeutic domain infectious metabolic disorders ophthalmology other or unspecifi ed

6 The Genopole Services Offer GENOPOLE S MANAGEMENT TEAM HAS BROADLY-BASED EXPERTISE IN TECHNOLOGY ASSESSMENT, LIFE SCIENCES RESEARCH, INVESTMENT ANALYSIS, MARKETING AND BUSINESS DEVELOPMENT. WE OFFER UNPARALLELED SERVICE WITH THE AIM OF PROVIDING QUALIFIED TECHNICAL AND SCIENTIFIC SUPPORT TO RESEARCH ACTIVITIES AND TO BIOTECHNOLOGY START-UPS AND GROWTH COMPANIES. Expertise and Know-How High-level scientific environment, industrial proximity especially pharmaceutics, advice of renown scientific and industrial experts, access to managerial training, privileged contacts for international prospecting, support of economic development partners (BioTeam Paris Region, Invest in France Agency ) Scientific Facilities International Convention Center Genocentre Multiple technological platforms and research infrastructures: 2 national platforms: Plant DNA Microarray Platform National Platform for DNA chip production. 7 technology platforms: Center for exploration and experimental functional research Microscope Platform (Bioinformatics annotation platform) Imaging and preclinical evaluation platform Open Biochip Center Mass spectrometry platform Augmented reality and virtual environment platform Optical Platform. 6 technical facilities: Transmission electron microscopy Atomic force microscope Cell sorting station NMR workstation Cell irradiator Biotech incubator. Opening soon: Center for bioproduction Center for biological resources Silanisation Platform. In the planning stage: Small animal imaging center.

7 Center of Excellence Biomanufacturing at Genopole Biotech companies often run in trouble when trying to produce their lead molecules. In order to resolve this situation and facilitate the development of life science businesses, Genopole is creating a biomanufacturing center in partnership with Mabgene company, an acknowledged specialist in GMP biomolecule production. It will offer companies and academic labs custom production of preclinical and clinical batches for phases I & II with quick turn-around times and competitive prices. In light of its choice of top-class bioreactors and filtration systems, the unit will equally be able to meet the requirements of pharmaceutical companies. All production operations will meet ISO 9001 standards and comply with GMP regulation. The center will open at the end of MediTech Healthcare Competitiveness Hub MediTech Healthcare (MediTech Santé) is a world class competitiveness cluster dedicated to the use of hi-tech in pharmaceuticals and healthcare. Thanks to decisive support from the Ile-de-France Regional Council, the region s General Councils (including that of the Essonne county) and Paris City Council, the MediTech Healthcare project has truly managed to federate all the Paris Ile-de-France region s stakeholders in the field of life sciences and healthcare. The hub s presidency has been entrusted to Jean-Claude Muller, senior Vice President of the Sanofi Aventis group, and Pierre Tambourin, Chief Executive of Genopole, has been elected Vice President. Six themes of excellence (neurology, oncology, infectious disease, medical imaging, molecular & cellular medicine and drug sciences & technology) have been chosen and will lead to collaborative projects between the public and private sectors. A new research hospital A university medical center will be created within the new hospital due to be built at the heart of the Evry-Corbeil campus. This development will promote synergy between researchers, entrepreneurs and clinicians and will also help transform the fruits of Genopole based fundamental and applied research into innovative medical therapies. The establishment of this new hospital (due to open in 2010) will favor the implementation of a skills spectrum linking life science researchers, bio-entrepreneurs and medical practitioners. The objective is clear: rapid transformation of research results into innovative medical therapies.

8 The Genopole Contacts Thierry Mandon, President of Genopole Pierre Tambourin, Chief Executive of Genopole Françoise Olier, Deputy Director of Genopole Véronique Dufey As the holder of a degree in Business Law from the University of Paris II and a Higher Degree in Finance from the Paris Business Administration Institute, Véronique Dufey has experience of two different facets of the world of start-ups. During her 5 years at the Crédit d Equipement des PME public-sector development bank, she was responsible for funding investment programs in small industrial businesses. In 1997, she founded one of the first ever companies to specialize in selective waste recycling on industrial sites. Véronique joined Genopole Entreprises in June 2001 and took over the leadership of the team in Patrick Faure With a PhD in immunology applied to public Health, Patrick Faure was appointed as Assistant Director of the Virology & Immunology Laboratory at the Cité Louis Pasteur in Brazzaville (Congo) to set-up research and diagnostic laboratories with the perspective to follow-up infected HIV and/or malaria patients. After his mission in Africa, he complemented his scientific background with a diploma in International Business Management at Paris Business School (ESCP). Patrick then joined the Genopole -Entreprises team in 1998 and has also been awarded a Certificate in Intellectual Property Promotion by the French Patent and Trademarks Office (INPI). Eric Lameignere Following his PhD in natural product chemistry at France s National Center for Scientific Research and some initial research experience at Rhône-Poulenc Rorer in the UK, Eric Lameignere completed his training with an MBA from the Euromed Business School in Marseille, France. Prior to becoming a business development director in a biotech startup, Eric spent more than ten years in big pharma, with a particular focus on the development and evaluation of biotech-pharma alliances. Eric joined Genopole Entreprises in September Cécile Ruiz-Fouquer As a graduate of the Higher Institute for Technology and Management (Noisy-le-Grand, France) and holder of a Diploma from the French Society of Financial Analysts, Cécile started her career as a biotech analyst at Close Brothers Equity Markets in Paris. She then took a position as a biotech analyst at Friedman, Billings, Ramsey International Limited in London, prior to joining the Genopole team in January Anne Walrafen Anne Walrafen is a graduate of the Ecole Polytechnique in Paris and acquired solid research experience during her PhD in neurobiology at the city s Salpetrière Hospital. During this time, she also provided teaching support for undergraduates at University of Paris VI. Anne then worked as a scientific analyst in the biotech VC department at Société Générale Asset Management, prior to holding a post as a junior business developer manager at ExonHit Therapeutics (also in Paris). Anne joined Genopole Entreprises in April Nicolas Godard Nicolas Godard graduated from the Paris-Grignon National Institute of Agronomy with a degree in Agricultural Engineering (option: Microbiology). He spent the first 8 years of his career managing R&D projects in yeast genetics within an international agrifood group, in close collaboration with its main overseas subsidiaries. Nicolas then completed his training with an MBA from the HEC School of Management in Jouy en Josas (France), after which he moved into the provision of consultancy services to budding entrepreneurs in the field of biopharmaceuticals. He joined the Genopole Entreprises team in January Marina Bunelle After training as a business translator at the Catholic University of Western France in Angers, Marina Bunelle obtained a Higher Degree in Finance at the Nantes Business Administration Institute and then worked as a consultant on setting up and running European Union-funded projects. In 1998, she joined the Pays de la Loire Regional Council (Nantes, France) with the mission of promoting the international development of local businesses. Marina has been part of the Genopole team since November 1999 and, since 2004, has dedicated herself exclusively to start-up financing activities via the Genopole Day One fund (of which she is a Management Board member). Réalisation a2i graphic - mars Photographs : A. Da Silva, J. Grison, X. Renauld Gabriel Mergui, Director of Genopole International gabriel.mergui@genopole.fr Marc Rébois, Director of SEM Genopole marc.rebois@semgenopole.fr Naceur Tounekti, Director of Global Infrastructure & Platforms naceur.tounekti@genopole.fr 2, rue Gaston Crémieux - CP Evry cedex, France - Tel: +(33) Fax: +(33)